| Description: |
IC50 Value: 1.09 uM (MTT assay in LNCaP-S14 cells) SMIP004 (N-(4-butyl-2-methyl-phenyl) acetamide) is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells. Unlike SMIP001, SMIP004 was found to downregulate SKP2 and to stabilize p27, although neither SMIP is a proteasome inhibitor. in vitro: Whereas SMIP012 and 016 were moderately toxic in normal fibroblasts, SMIPs 001 and 004 showed substantial cancer cell specificity being at least five times more potent in LNCaP-S14 than in IMR90 cells, treatment with either MG132 or SMIP004 increased p27 half-life to > 6 h. Both SMIP001 and 004 led to a strong increase in the recruitment of p27 to CDK2, while SMIP001 also slightly increased coprecipitation of p21 (Figure 6c). SMIP004 also reduced the amounts of cyclins E and A retrieved with CDK2. This was paralleled by a marked downregulation of cyclins E and A upon SMIP004 treatment. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony Formation in soft agar, and cell death . in vivo: SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice. Clinical trial: N/AFor the detailed information of SMIP004, the solubility of SMIP004 in water, the solubility of SMIP004 in DMSO, the solubility of SMIP004 in PBS buffer, the animal experiment (test) of SMIP004, the cell expriment (test) of SMIP004, the in vivo, in vitro and clinical trial test of SMIP004, the EC50, IC50,and Affinity of SMIP004, Please contact DC Chemicals. |
